SCHEMBL15854366

SCHEMBL15854366

CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)OCC(=O)c1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.51
EPHX2 P34913 1/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
UCHL1 P09936 1/20 0.45
KLK7 P49862 1/20 0.45
LMNA P02545 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 2/20 0.44
HRH2 P25021 1/20 0.44
HRH1 P35367 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
HSD17B10 Q99714 2/20 0.43
TSHR P16473 2/20 0.42
TLR2 O60603 1/20 0.42
TLR1 Q15399 1/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17396032 1.00 NPC1 (0.51) NPC1EPHX2MEN1KMT2AUCHL1
SCHEMBL754137 0.91 NPC1 (0.53) NPC1EPHX2MEN1KMT2AUCHL1
SCHEMBL11910978 0.91 NPC1 (0.53) NPC1EPHX2MEN1KMT2AUCHL1
SCHEMBL203942 0.90 NPC1 (0.52) NPC1EPHX2MEN1KMT2AUCHL1
SCHEMBL15854471 0.90 LMNA (0.53) NPC1EPHX2MEN1KMT2AUCHL1
SCHEMBL15848405 0.90 LMNA (0.53) NPC1EPHX2MEN1KMT2AUCHL1
SCHEMBL2706083 0.90 NPC1 (0.52) NPC1EPHX2MEN1KMT2AUCHL1
SCHEMBL18845559 0.89 NPC1 (0.49) NPC1EPHX2MEN1KMT2AUCHL1
SCHEMBL10092365 0.89 NPC1 (0.51) NPC1EPHX2MEN1KMT2AUCHL1
SCHEMBL607421 0.89 NPC1 (0.51) NPC1EPHX2MEN1KMT2AUCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9868758-B2 Betulinic proline imidazole derivatives as HIV inhibitors HETERO LABS LIMITED (IN) 2018-01-16 US disclosed
US-9868758-B2 Betulinic proline imidazole derivatives as HIV inhibitors HETERO LABS LIMITED (IN) 2018-01-16 US disclosed
US-20170129916-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2017-05-11 US disclosed
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2017-05-11 US disclosed
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2017-05-11 US disclosed
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2017-05-11 US disclosed
US-20170129916-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2017-05-11 US disclosed
US-9637516-B2 Betulinic acid proline derivatives as HIV inhibitors HETERO RESEARCH FOUNDATION (IN) 2017-05-02 US disclosed
US-9637516-B2 Betulinic acid proline derivatives as HIV inhibitors HETERO RESEARCH FOUNDATION (IN) 2017-05-02 US disclosed
WO-2016001820-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2016-01-07 WO disclosed
WO-2016001820-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2016-01-07 WO disclosed
US-20150337004-A1 NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2015-11-26 US disclosed
US-20150337004-A1 NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2015-11-26 US disclosed
WO-2014105926-A1 NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2014-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129916-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS BET1, PRR12, PREP NPC1 1111/4885EPHX2 3717/4885MEN1 3967/4885
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS BET1, PRR12, IMPA1 NPC1 1201/4885EPHX2 3660/4885MEN1 4006/4885
US-20150337004-A1 NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS BET1, PRR12, PELP1 NPC1 1195/4885EPHX2 2877/4885MEN1 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.